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Abstract
BACKGROUND: Nationwide more than 90% of cervical cancer cases are caused by the human
papilloma virus (HPV). Cervical cancer can be largely prevented by administration of the HPV
vaccine for children before becoming sexually active. However, vaccination rates in the United
States, remain low at 60%, and only 39.7% through series of completion, despite the strong
evidence to support the effectiveness of the HPV vaccine. Research indicates a clinician’s
recommendation, providing information and opportunity for discussion about the vaccine are
strong motivators for parents to vaccinate their children, regardless of ethnicity. This study
addresses the barriers to parent/caregiver intent to vaccinate, and clinician time to discuss the
vaccine, by implementing an RN-led educational intervention regarding the HPV vaccine for 1117 year-old children.
Purpose: The purpose of this study is to evaluate the effect of an RN-led educational
intervention on 1) parent/caregiver intent to initiate the HPV vaccination 2) to evaluate effect on
HPV vaccination rates, and 3) evaluate satisfaction with the education provided in a pediatric
primary care clinic.
Methods: The design was a multi-phased quasi- experimental pre/post baseline assessment study
that had 4 phases: a chart review (Phase 1), a study introduction (staff meeting: Phase 2), an
educational intervention (Phase 3), and an outcome evaluation (Phase 4). The RN-led education
intervention focused on the caregiver of adolescent children to address questions and barriers
regarding the HPV vaccine. The setting for all phases of the study were done at a pediatric
primary care clinic in Southern Indiana. The clinic is responsible for the management and
treatment of pediatric patients. The sample for the study included: any caregivers of 11-17 yearold children being seen in the office for a non-acute visit. These children had never received any

2

doses of the HPV vaccine and were English speaking. Exclusion criteria was any caregiver of a
11-17 years of age being seen for a sick visit, or any that had previously received any dose of the
HPV vaccine. Evaluation methods included: chart audit tool that recorded child demographics,
information on HPV counseling provided, a pre- and post- educational survey to measure
knowledge, intent to vaccinate, and evaluation of the educational intervention.
Results: Pre- intervention surveys indicated most parents had heard of HPV vaccinations (80%),
knew that it was recommended (87%), and felt it was part of cancer prevention (100%). While
scores increased, there were no significant differences between pre- versus post-educational
intervention surveys in caregivers who intended to have their child receive the vaccination today
(M=4.3 vs M=6.7) or in the future (M=5.9 vs 6.9). The HPV vaccination rates for the initial dose
of the vaccine increased from 19.1% to 40.8%, and for any dose from 58.4% to 64.3%. These
results indicate the clinic surpassed their goal of 60% after the intervention was provided. Postsurvey results showed caregiver evaluation was favorable when measuring satisfaction and
helpfulness with educational intervention provided. Vaccination rates improved after a 1:1 brief
educational discussion between the caregiver the RN; this finding suggests that the 1:1
interaction to discuss facts and answer questions may be associated with improved vaccination
rates.
Conclusion: HPV vaccination rates increased after a brief educational intervention regarding the
HPV vaccine was provided to caregivers of 11-17 year-old children. This finding suggests that
education may have been beneficial; however, overall vaccination rates were still low and the
need for improvement remains. Future work should seek to identify which specific elements of
this intervention contributed to the success and strategies to sustain the improvements as well as
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identify additional strategies to further improve vaccination rates. An important next step is to
initiate efforts to increase vaccine series completion rates.

4

Acknowledgements
I would first like to thank my amazing committee members, Dr. Elizabeth Tovar, Dr.
Angie Grubbs, and Dr. Marianne Hutti for their countless hours of expertise and guidance with
the instruction and completion of this project. To Whitney Kurtz-Ogilvie the writing specialist at
the University of Kentucky, thank you for reviewing my paper and providing such helpful
feedback. Also, thank you to Dr. Amanda Wiggins the statistician for all of her help in analyzing
the data that was collected for this project.
I would like to thank God for giving me the strength and perseverance to finish this
program and providing a path for me to provide faith- based medicine as a provider. Through
Him all things are possible. I look forward to using the gifts that He has given me as a caregiver
to pursue Him always and walk the path He provides for me. I would also like to acknowledge
and recognize my amazing and loving husband Jimmy Pierce for always supporting my passions
and walking through this journey with me. Goodness gracious he is such a blessing and has
never stopped, not even once at having faith in my successes. To my three beautiful children
Cooper, Gleason, and Maverick who showed constant love and affection and enjoyed many
conversations and video chats with me during this process. I hope that my passion and endurance
through this program fulfills their love for education and pursuing their hopes and dreams. To
my wonderful parents Debbie and Stephen, for their constant love and support throughout the
program and always. Their love of education and gentle nudges are what pushed me to pursue
my career in nursing.
Lastly, I would like to thank my “village,” an amazing group of family and friends that
encouraged me during this time. We have laughed and cried many times together during this

5

process. Their love and encouragement have truly meant the world to me, when I felt like I was
losing my grips they were there to hold me steady and strong.
To the students and preceptors I met along this journey, each one of you has had an
impact on my learning experience. I appreciate all of the insight each of you were able to
provide. I am so excited about what the future has in store for all of us!

6

Table of Contents
Acknowledgements………………………………………………………………………………..5
List of Appendices….....…………………………………………………………………………..8
List of Tables………………………………………………………………………………….…..9
Introduction………………………………………………………………………………………10
Purpose..………………………………………………………………………………………….12
Theoretical Framework.……………………………………………………………………….…13
Methods….…………….…………………………………………………………………….…...14
Procedures.……………………………………………………………………………………….16
Data Analysis.……………………………………………………………………………………21
Results……………………………………………………………………………………………21
Discussion………………………………………………………………………………………..24
Implications for practice…………………………………………………………………………30
Limitations……………………………………………………………………………………….31
Conclusions……..……………………………………………………………………………......32
References…………………………………………………………….………………………….34

7

List of Appendices
Appendix A Educational Intervention Outline ………………………………………………….36
Appendix B Consent Form …………………………………………………………………..….37
Appendix C Cover Letter………………...………………………………………………………42
Appendix D Chart Audit Tool………………………...…………………………………………44
Appendix E Parent/Child Pre- Educational Intervention Survey………………………………..45
Appendix F Parent/Child Post- Educational Intervention Survey…………………………...…..46
Appendix G Educational Pamphlet ………………………...…………….,……………………..47
Appendix H Staff Member Script for Introduction of Study………….……..…………………..48
Appendix I HIPPA for Research Purposes ……………..………………….……………………49
Appendix J Staff Meeting Invitation ………………………………………….…………………51
Appendix K Staff Meeting Agenda ……..………………………………….…………………...52
Appendix L Script for Parent/Caregiver Educational Intervention...….………………………...53

8

List of Tables
Table 1 – Pre- and Post-educational Intervention Chart Review/Study Demographics……......54
Table 2 – Pre- and Post-Educational Intervention Surveys ……………………..……………...55
Table 3 – Chart Audits Pre- and Post/Vaccination rates for administration of the HPV
vaccine…………………………………………………………………………………………...56
Table 4 – Pre- and Post- Vaccination Rates……………………...……………………………...56
Table 5 – Pre-educational intervention knowledge of the HPV vaccine..………...………….....57
Table 6 - Post- Educational Intervention Survey Results………………………………………..58

9

Introduction
More than ninety percent of cervical cancer cases are caused by the human papilloma
virus (HPV). The Center for Disease Control (CDC; 2019) reports 300,000 cervical precancerous
cases, 44,000 cervical cancer cases, and 4,000 deaths related to HPV every year in the United
States. Human Papilloma Virus affects men as well as women. Every year in the U.S 25,000
women and 19,000 men get cancers caused by HPV, comprising nearly four out of every ten
cancer diagnoses caused by the virus (CDC, 2019). Cervical cancer was once the leading cause
of cancer deaths among women in the U.S., but the HPV vaccine and cervical cancer screening
have made it one of the most preventable cancers. Screening alone will not protect men or
women from HPV cancers. The HPV vaccination helps prevent these cancers by preventing the
infections that cause them (CDC, 2019).
Cancers and diseases secondary to the human papilloma virus (HPV) may be prevented
through the administration of the HPV vaccination. However, vaccination coverage percentages
remain below the standards set by the Healthy People 2020 initiatives (Harris, 2017). These
initiatives set a goal that 80 percent of adolescent boys and girls from ages 13 to 15 years should
receive the three-dose series of the HPV vaccine through completion (Smulian, Mitchell, &
Stokley, 2016). At present, however, approximately only 60 percent of girls and boys ages 13 to
17 years have received only one dose of the vaccination; and only 39.7% received the
vaccination through to completion of all three doses (Smulian, Mitchell, & Stokley, 2016). In
2014, the rates among boys aged 13 to 17 years were considerably lower with 41.7% receiving
only the first dose, and only 21.6% completing the three-dose series (Smulian, Mitchell, &
Stokley, 2016). Therefore, it is imperative that primary care providers work toward efforts to
increase vaccination coverage.
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In a 2014 study, Holman found that lack of parental knowledge of vaccination was a
major barrier to providing the HPV vaccine to adolescents. For example, a significant number of
parents in that study reported needing more information before vaccinating their children. The
parents voiced concerns about the vaccine’s effect on sexual behavior and demonstrated a low
perception of their children’s risk of contracting HPV. These parents also identified social
influences, irregular preventive care, and vaccine cost as potential barriers. Additionally, some
parents of sons reported not vaccinating their sons because of the perceived lack of direct benefit.
Parents consistently cited health care professionals’ recommendations as one of the most
important factors in their decision to vaccinate their children (Holman, 2014). In a 2011 study,
the proportion of physicians who reported “always” recommending HPV vaccine was 40% for
early adolescent girls, 55.3% for middle adolescents, and 51.8% for late adolescents/young
adults (Vadaparampil, 2011). A study from the CDC (2019) states that providers identified that
limited staff resources, challenges of electronic health records, issues with state immunization
registries, patient misinformation about vaccines and vaccine stigma, cultural/language barriers,
competing priorities, levels of funding, staff buy-in, training needs, and low health literacy were
barriers to recommending the HPV vaccine (CDC, 2019).
Continued efforts are needed to ensure that health care professionals and parents
understand the importance of vaccinating adolescents before they become sexually active.
Research suggests that further efforts are also needed to reduce missed opportunities for HPV
vaccination when adolescents interface with the health care system. A study from the American
Academy of Pediatrics (2014) concluded that many missed opportunities for HPV vaccination
occur not because parents and providers feel that vaccination is unimportant but because both
parties tacitly agree to delay vaccination until there is a perception that the adolescent is at risk
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for sexual activity (AAP, 2014). Health care professionals may benefit from guidance on
communicating HPV recommendations to patients and parents. Dempsey (2019) and Chuang
(2017) suggest future practices should include continuing education for providers on the
importance of educating parent/caregivers of adolescents ages 11-17 years old using improved
information technologies (IT) techniques (Dempsey, 2019). Chuang (2017) also recommends
placing posters and prompts in the exam rooms and in their individual office spaces as a way of
providing additional education on the vaccine to parents/caregivers.
Purpose
This project was initiated to improve rates of the administration of the HPV vaccination
in the pediatric primary care setting. The setting for the study was the St. Vincent Pediatric
Clinic in Salem, Indiana. The clinic identified that at their current 58.4% vaccination rate, they
were falling short of their goal of 60% of patients receiving the HPV vaccine each month. The
ultimate clinic target goal was set at 80% to meet the Healthy People 2020 goal of and 80% HPV
vaccination rate (Harris, 2017). The providers at the clinic verbalized the need for an
intervention to aid in meeting their target monthly goal. They recommended patient/caregiver
education because they identified the lack of education as a major barrier.
This project implemented and evaluated a parent/caregiver educational intervention to
increase intent to vaccinate and evaluate vaccination rates among 11-17- year-old adolescent
patients and their caregivers. The specific aims were to evaluate the effect of an RN- led
educational intervention on:
1) Caregiver intent to initiate the HPV vaccine for their child
2) HPV vaccination rates for the clinic
3) Satisfaction with the educational intervention provided to the caregivers
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Theoretical Framework
The theoretical framework that shaped and contributed best to the design of this study
was the Consolidated Framework for Implementation Research (CFIR; Garbutt, 2018). Garbutt
(2018) used the CFIR to develop a pragmatic intervention to increase implementation of the
HPV vaccine guideline recommendation and HPV vaccination rates in pediatric primary care
practices (Garbutt, 2018). The CFIR was used to systematically investigate and characterize
factors that may strongly influence vaccine use. Then the Behavior Change Wheel (BCW) and
the Theoretical Domains Framework (TDF) were used to analyze provider behavior and identify
behaviors to target for change and behavioral change strategies to include in the intervention.
The BCW and TDF identified facilitators and barriers to guideline use across the five CFIR
domains: most distinguishing factors related to provider characteristics, their perception of the
intervention, and their process to deliver the vaccine. The CFIR domains using the theory
included: intervention characteristics, outer setting, inner setting, characteristics of individuals,
and process. Targeted behaviors using this theory suggested that providers should recommend
the HPV vaccine the same way and at the same time as the other adolescent vaccines, to answer
parents’ questions with confidence, and to implement a vaccine delivery system (Garbutt, 2018).
According to Garbutt (2018), the intervention should be aimed at improving provider’s
capability (knowledge, communication skills) and motivation (action planning, belief about
consequences, social influences) regarding implementing guideline recommendations, and
increasing their opportunity to do so (vaccine delivery system). Behavior change strategies
included: providing more information, adding communication skill training with graded tasks
and modeling, feedback of coverage rates, goal setting, and social support. The theory
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demonstrates strategies that were combined in an implementation intervention to be delivered
using practice facilitation, educational outreach visits, and cyclical small tests of change.
This framework was consistent with goals set forth for this study. Using the CFIR theory
and the associated BCW and TDF helped facilitate the development of a pragmatic, multicomponent implementation intervention to increase use of the HPV vaccine in the primary care
setting. These implementation strategies, according to theory, should be adopted into the
primary care offices to increase the use of clinical recommendations towards the HPV vaccine.
Methods
The study design was a multi-phased quasi experimental pre/post baseline assessment
study that had 4 phases: a chart review (Phase 1), a study introduction (staff meeting: Phase 2),
an educational intervention (Phase 3), and an outcome evaluation (Phase 4). The project focused
on working with the parent/caregiver of adolescent children to address questions and barriers
regarding the HPV vaccine. Providing education and an opportunity to discuss questions and
answers with the parent/caregiver may help to overcome knowledge deficit and correct
misinformation. Overcoming barriers by providing an educational discussion may have an
impact on intent to initiate the HPV vaccination, therefore, leading to an increase in HPV
vaccination rates.
Setting
The setting for all phases of the study was St. Vincent Pediatric Clinic located in Salem,
Indiana. The clinic is part of a large healthcare organization, Ascension Healthcare. Annually,
the clinic is responsible for the management and treatment of pediatric patients in Southern
Indiana. This clinic is responsible for the management and treatment of pediatric patients. The
clinic staff consisted of: two APRN’s, one RN, two MA’s, and a front desk receptionist. On
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average between the two providers they see approximately 70 patients per week. The clinic
baseline rate of any dose of the HPV vaccine was 58.4%. They were falling short of their goal of
60% of adolescents receiving the HPV vaccine each month with the ultimate goal of reaching the
Healthy People 2020 initiative of 80% of the adolescents being vaccinated (Harris, 2017). The
providers at the clinic verbalized the need for an intervention to aid in meeting their targeted
monthly goal and they suggested caregiver education. The providers identified a lack of
knowledge amongst caregivers, and the providers felt they do not have time to discuss the
vaccine during the visit. Therefore, this project implemented and evaluated an RN led caregiver
educational intervention to increase intent to vaccinate and evaluate vaccination rates in the
clinic.
Sample
For phase one, a convenience sample of 100 chart reviews were completed on medical
records from patient charts dated October 15, 2019 through January 15, 2020 were reviewed to
determine the clinic’s baseline HPV vaccination rate. Criteria for inclusion in the educational
intervention study were any parent/caregiver of a child 11-17 years of age being seen in the
office for a non-acute visit. Exclusion criteria for the study included 1) any parent/caregiver of a
child 11-17 years of age being seen for a sick visit, 2) any parent/caregiver of a child that is nonEnglish speaking, and 3) any parent/caregiver of a child that does not meet age criteria of 11-17
years old. Variables that were included in the chart review were whether counseling was
provided, who provided vaccine counseling, whether the vaccine was offered by the provider,
whether the patient accepted/declined/deferred vaccination, if the vaccine series was initiated,
and if it was completed. Gender, age, and race were also recorded. A chart audit tool was used
to record this information (Appendix D).
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Phase four of the study was done after one month of providing the educational intervention.
The follow-up chart review evaluated vaccination rates for adolescents seen in the office by a
provider during the time period of January 15, 2020 to February 15, 2020. The post-chart audit
included a convenience sample of 100 chart reviews on medical records dated January 15, 2020
to February 15, 2020. The charts were reviewed until a sufficient sample size of 100 was
reached. Inclusion and exclusion criteria were the same for both pre- and post- audit chart
reviews.
Procedures
The study started with a baseline chart review to establish current vaccination rates. The
study goal was to educate 120 parents/caregivers on the significance of initiation of the first dose
of the HPV vaccine during their well-child exam. The DNP project was implemented at this
location to aid in increasing first dose HPV vaccination rates and provide an RN-led educational
intervention to improve intent to vaccinate by providing a question and answer session with the
parent/caregiver, therefore helping the office increase vaccination rates and reach their current
goal.
Phase 1 – Chart Review
Phase 1 included a chart review of recent medical records to determine the baseline
vaccination rate at the clinic. One hundred medical records were randomly selected from charts
dated October 15, 2019 through January 15, 2020 meeting age criteria 11-17 years old until a
sufficient sample size of 100 was obtained. Variables that were determined by reviewing the
chart included whether vaccine counseling was provided, who provided vaccine counseling,
whether the vaccine was offered by the provider, whether the patient accepted/declined/deferred
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vaccination, if the vaccine series was initiated, and if it was completed. Gender, age, and race
were also recorded. A chart audit tool was used to record this information (Appendix D).
Phase 2 – Study Introduction/Staff Meeting
Once the chart review was completed, a staff meeting was held (Phase 2). All staff
working in the clinic as providers, nurses, medical assistants, and/or at front desk were invited to
attend the staff meeting through flyers posted in the office. There were 6 possible participants
including: 2 APRN’s as providers, 1 RN, 2 MA’s, and one front desk receptionist. Invitation to
staff meeting attached (Appendix J). All clinic staff were informed of the study using a script as
a guide for the discussion (Appendix K). The purpose of the staff meeting was to inform them of
the educational intervention that was going to be provided by the PI in the clinic. Educational
pamphlets and pre- / post- educational intervention surveys were discussed to familiarize the
staff with the content the PI was planning to provide to caregivers.
Additionally, the staff meeting was designed to inform the staff of their current baseline
rate of vaccination and to describe the educational intervention and process that was going to be
provided by the PI in the clinic. The clinic staff was not involved in conducting the study.
Educational pamphlets (Appendix G) and pre-/ post- surveys (Appendices E and Appendix F)
were discussed to familiarize the staff of the content the PI was planning to provide to
parents/caregivers. Any questions the staff had regarding the educational intervention were
answered by the PI.
Phase 3 – Clinic-Led Educational Intervention
The first contact with the parent/caregiver was the staff member assigned to the front
desk of the clinic. A script for the introduction of the study was given to the staff member
(Appendix H). The educational intervention planned was outlined by script (Appendix L) with
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the parent/caregiver of the adolescent regarding the HPV vaccine. The PI answered any
questions the parent/caregiver had regarding the vaccine. The primary investigator reviewed the
educational pamphlet (Appendix G) with the patient. Any questions or concerns were addressed
during the discussion.
Step 1. Staff member at the front desk distributed the cover letter provided (Appendix
C). The cover letter was given to the parent/caregiver of adolescents in the identified age group.
Step 2. The child and caregiver were placed in an exam room by the medical assistant
(MA). The MA provided the educational pamphlet to parent/caregiver (Appendix G). The
parent/caregiver was instructed to review the material. The PI was invited in only if the
parent/caregiver gave verbal agreement to participate in the study. The RN or MA notified the PI
of the verbal agreement. Pre-educational survey (Appendix E) was given to the parent/caregiver
per the PI if they were interested in the study.
Step 3. The primary investigator ensured that the parent/caregiver understood the study
and confirmed by verbalizing understanding, per a verbal response from the parent/caregiver. A
verbal response had to include an answer of yes or no to the question: “Do you understand the
study?” Answering yes to the question was considered as verbal understanding of the study. The
PI requested that the pre-educational intervention survey be filled out prior to beginning the
educational intervention with the parent/caregiver.
Step 4. The educational intervention occurred prior to the office visit with the provider,
after the patient had been roomed and was waiting for the provider. The goal was to speak with
the parent/caregiver prior to their interaction with the provider. However, consideration of clinic
flow and provider schedules was always a priority, so at times the PI spoke with the
parent/caregiver after the provider visit was complete. The PI discussed the vaccine with the
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parent/caregiver, using the educational pamphlet as the guide. Any questions regarding the
vaccine were discussed. The educational pamphlet was reviewed (Appendix G). The script for
this discussion is attached (Appendix L). All questions regarding the vaccine were answered by
the PI, who is a licensed RN and DNP-FNP student.
Step 5. After discussing the vaccine and addressing all questions the parent/caregiver
had, the parent/caregiver of the adolescent was then asked about their intent to vaccinate. The PI
provided a post-educational intervention survey to be completed by the parent/caregiver
(Appendix F). The decision to vaccinate was documented by the PI. The parent/caregiver was
asked to leave the pre-/post- educational intervention surveys in the exam room after the visit to
be collected by the PI. If the parent/caregiver chose to receive vaccination, the PI facilitated
vaccine initiation by informing the provider who then ordered the vaccine administration to be
given by the certified MA/RN.
Step 6. The pre- and post- educational intervention surveys (Appendix E and Appendix
F) were used to evaluate whether the educational intervention increased first dose administration
of the HPV vaccine and was successful in overcoming child/parent knowledge barriers of the
HPV vaccine.
Phase 4 - Chart Review
After one month of providing the educational intervention to parent/caregivers of the
adolescents aged 11-17 years old, a follow-up chart review evaluated post-intervention rates
(Phase 4). Data were collected from 100 charts selected by convenience sampling technique to
determine if the vaccination goal was met using the same chart audit tool (Appendix D) for post
assessment. The charts were selected by convenience sampling technique from children aged 1117 years old that were seen in the clinic by a provider during the time- period of January 15,
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2020 to February 15, 2020. Data were collected from the charts, included patient age, gender,
and race, whether counseling was offered regarding HPV vaccination, by whom, whether the
HPV vaccine was offered, whether the patient accepted/refused/deferred vaccination, whether
the HPV vaccine series was initiated, and whether the HPV vaccine series was completed. Data
were collected from the chart audits by the PI. The survey data were entered into SPSS, version
25, and analyzed by a statistician. The St. Vincent (Ascension) Institutional Review Board
granted approval (#R20190145) prior to the start of this project.
Instruments
Parent/Child Pre-Educational and Post- Educational Intervention Surveys.
Parent/Caregiver knowledge of the HPV vaccine and parent/caregiver intent to initiate
the HPV vaccination was measured by an investigator-developed instrument called the
Parent/Child Pre-Educational Intervention Survey. This is a 6-item survey. Two items are
answered with “yes/no” responses, two are answered with “true/false” responses, and two are
answers with a 10-point Likert-type scale (with 0 being no chance and 10 very likely). The preeducational survey was designed to measure knowledge of the HPV vaccine and intent to
vaccinate prior to the educational intervention. The Post- Educational Intervention Survey was
the same as the Pre-educational Intervention Survey for questions 2-4, and then the post- survey
added questions 5-7 that were designed to measure intent to administer the vaccine after an
educational intervention was given. The final question asked if the RN led educational
intervention was helpful in their decision to vaccinate their child?
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Improving Rates of First Dose Administration of the HPV vaccine Chart Audit
Tool.
Chart audits were conducted to determine the baseline vaccination rate for the clinic as
well as the post-intervention vaccination rate for the clinic. An instrument called the Improving
Rates of First Dose Administration of the HPV Vaccine Chart Audit Tool was used to ensure
consistency in data collection from randomly selected charts. The following information was
collected: gender, age, race, whether counseling on the HPV vaccine was provided; whether the
HPV vaccine was offered; patient’s response if vaccine was offered; whether the HPV vaccine
series was initiated today; whether the vaccine series initiated or completed prior to this visit;
and the date documented for doses of the vaccine the child received prior to the study.
Data Analysis
Descriptive statistics were used to analyze variables such as age, gender, and ethnicity.
HPV vaccination rates were examined pre- and post-educational intervention using Chi-square
test. Means of interval variables on the pre- and post-educational intervention survey responses
were analyzed using an independent samples t-test. All data analysis was conducting using
SPSS, version 25. Microsoft Excel was used to create frequency tables.
Results
Phase 1: Baseline Chart Review
The sample for the baseline chart audits were predominantly Caucasian (97%, n=97) and
female (females 56%, n=56; males 44%, n=44) with the average age of 13.9 years (pre-, n=100,
see Table 2). One hundred medical records were charts selected by convenience sampling
technique dated October 15, 2019 through January 15, 2020 meeting age criteria 11-17 years old
until a sufficient sample size of 100 was obtained. Of the 100 charts selected by convenience
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sampling technique, 100% were counseled by the provider who was an APRN, 100% were
offered vaccine, and 19.1% (see Table 1) chose to be vaccinated.
The results of the study were based on vaccination rates for those who had not received
any of the vaccine series prior to this visit. One hundred four children had received doses of the
HPV vaccine through completion. There were 47 eligible charts for the pre-audit. Table 3
presents data for those receiving their initial dose of the HPV vaccine before the intervention.
From this total of 47, 9 had been vaccinated pre- intervention, leaving 38 who had chosen not to
be vaccinated prior to the intervention.
There were 15 caregivers in the intervention group. Prior to the education intervention,
parent/caregivers were given the opportunity to share their knowledge and intent to vaccinate
with a pre-educational intervention survey (Appendix E) (Table 5). These parents/caregivers had
high knowledge scores in the baseline assessment. In the pre-intervention surveys, most parents
knew that it was recommended (80%), and felt it was a part of cancer prevention (100%); see
Table 5). Using a scale of 0-10, with 10 being absolutely planning to receive the vaccination that
day and 0 not planning on receiving the vaccine at all. To receive the vaccination today (M=4.3)
or in the future (M=5.9, Table 2).
Phase 2: Chart Review
The sample for the post- intervention chart audits were predominantly Caucasian (94%,
n=94), and evenly split between females and males (females {50% n=50} and males {50%,
n=50}), with the average age of 13.6 years (n=100) (see Table 2). Of the 100 charts selected by
convenience sampling technique, 100% were counseled by the provider, the counseling was
provided by an APRN, 100% were offered vaccine, and 40.8% (see Table 3) chose to be
vaccinated.
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Following the educational intervention parent/caregivers were given the opportunity to
share feedback of the educational intervention (post-educational intervention survey, Appendix F)
and their intent to vaccinate (Table 2 and Table 3). After the educational intervention, of those
who did not complete their series of vaccination that day (n=96), there was a significant increase
from 19.1% (pre-) to 40.8% (post-) who chose to be vaccinated with their initial dose of the HPV
vaccine (p=0.21; see Table 1). According to the pre- versus post- educational intervention results,
satisfaction overall with helpfulness, on a scale of 0-10 with 10 being the most helpful, parents
thought the intervention was helpful (M=9.3, SD=1.3), the pamphlet was helpful (M=9.4, SD 1.3),
and the principal investigator discussion was helpful (9.7, SD 1.0) (See Table 5).
The results of the study were based on vaccination rates for those who had not received
any of the vaccine series prior to this visit. One hundred four children had received doses of the
HPV vaccine through completion. There were 49 eligible charts to review for the post-audit. Table
3 presents data for those receiving their initial dose of the HPV vaccine before and after the
intervention. Per the chart reviews out of 49 total, there were 20 post- intervention patients that
chose to be vaccinated and 29 chose not to be vaccinated. This shows a significant increase, from
19.1% to 40.8% for those who received their first dose of the vaccine. Unfortunately, there is no
way to tell which part of the convenience sample post- intervention received the educational
intervention.
Table 4 presents the data for the pre- and post- intervention vaccination rates. Prior to the
educational intervention, the clinic reported their vaccination rates at 58.4% of adolescents who
had received some or all of their vaccination series. The clinic monthly rate for vaccination for
February 2020, following the study, was 64.3% (p= .044), see Table 4). These results indicate the
clinic surpassed their goal of 60% after the intervention was provided in the clinic.
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Discussion
The purpose of this study was to evaluate the effect the effect of an RN-led educational
intervention and the impact of the intervention on the intent to vaccinate and vaccination rates in
a specific pediatric primary care setting. The HPV vaccination rates for the initial dose of the
vaccine increased from 19.1% to 40.8% (p=.21, see Table 3) and for any dose from 58.4% to
64.3% (p=.044, see Table 4). These results indicate the clinic surpassed its’ goal of 60% after
the intervention was provided. The increase in parents/caregivers choosing to vaccinate their
child after the educational intervention suggests that the intervention may have led to an increase
in vaccination rates. Although this study was not designed to test for causation, it is encouraging
that there was a significant improvement in vaccination rates after a brief and simple educational
session with the parent/caregivers. Because baseline knowledge scores were already high and
perceptions started out positive, it is not likely the parent/caregivers learned new information;
however, it is possible that simply discussing the HPV vaccine brought it to the forefront of their
attention and thus made them more likely to vaccinate.
The finding of improved vaccination rates for both first dose and consecutive doses of the
HPV vaccine are encouraging, however rates are still well below the national goal of 80%
(Harris, 2017), and this low rate may lead to preventable morbidity and mortality related to HPV
cancers. There could be many reasons for the rates remaining low; including religious or
personal beliefs regarding vaccinations, and the lack of understanding of the reasoning behind
initiating the series at such a young age (Vadaparamil, 2014). It is also supported in the
literature that the barriers that exist can be overcome by increasing education to caregivers
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(Vadaparamil, 2014). It is likely that the brief education to caregivers may have played a role
with the increase in rates. However, knowledge is a necessary, but not sufficient, precursor to
decision-making and future studies should expand beyond just knowledge barriers. Further
investigation is needed to identify how to overcome those perceptions and what specific element
of the session led to the improvement in rates. Vaccination rates improved after a 1:1 10-15
minute educational discussion between the caregiver and the RN; this finding suggests that the
1:1 interaction to discuss facts and answer questions can improve vaccination rates. Additionally,
satisfaction scores when rating helpfulness were high, suggesting positive interaction between
the parent/caregiver and provider. Next steps would include how to best incorporate this 1:1
educational opportunity into standard practice.
The finding of low vaccination rates is consistent with the national average of
approximately 60% of girls and boys, ages 13 to 17 years who have received only one dose of
the HPV vaccination (Smulian, Mitchell, & Stokley, 2016), but it is encouraging that this clinic
increased rates from 19.1% to 40.8% (see Table 3), which is now closer to meeting the national
average. Another recommendation would be to change the educational intervention to make it
more interactive with both the parent and the child (Dempsey, 2019). This educational session
took the PI around 10-15 mins to provide. It was an open discussion, although the child was
present, the discussion was directed towards the caregiver. During the 1:1 discussion the PI
clarified and allowed the parent to ask any questions they had about the HPV vaccine. During the
educational sessions some of the barriers, misperceptions, and concerns expressed by the
caregivers included: lack of benefit for their child, perception of their child being low risk, they
did not understand why the HPV vaccine was initiated at such a young age, and they felt the
HPV vaccine was falsely advertised. Using proper engagement methods, aimed towards
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involving both participants, is important to ensure both the parent and child understand the
education being provided.
The parent/caregiver participants in this study all had good baseline knowledge scores
and positive perceptions about the importance of administering the HPV vaccine, which suggests
that they are knowledgeable, willing, and able to complete the first dose administration of the
HPV vaccine. However, time to provide education regarding the vaccine appears to be a
significant barrier that needs to be addressed for the providers in the clinical setting.
In a study by Carhart (2018), time constraint and inconsistent or lack of recommendation
by the health care provider (HCP) were found to be barriers to parents’ decision to vaccinate.
One stakeholder in the study stated that providers are not making the strong recommendation for
the vaccine and organizations are not holding them accountable (Carhart, 2018). This is a barrier
in a lot of places, but in the study site the providers recommended it 100% of the time.
Therefore, provider recommendation is not a reason for low rates in this clinic, therefore, other
factors need to be considered.
The vaccine has had a huge impact on preventing HPV, yet vaccination rates remain low
despite the strong evidence to support how it prevents cervical cancers and related morbidity and
mortality rates (CDC, 2019). It is essential that we understand factors that influence the decision
to vaccinate and implement evidence-based strategies to improve vaccination rates. Several
barriers to vaccination were identified in this study may be categorized as; provider- based,
patient/caregiver- based, and system- based.
Providers in the clinic recognized that they recommend the HPV vaccine most of the time,
but do not have time to discuss these recommendations with parents in depth. Patient/Caregiver
barriers found in the literature reported parents needing more information before choosing to
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vaccinate their child (Vadaparamil, 2014). Parents in this study reported feeling the vaccination
would have a negative effect on sexual behavior and most of them felt that their child’s risk of
contracting HPV was low. Other studies (Dempsey, 2019) and (Chuang, 2017), identified more
barriers such as; social influences, irregular preventative care, and vaccine cost.
System- based barriers include the absence of reminder systems and problems within the
electronic health records. It was identified by (Vadaparamil, 2014) that knowledge and
perception of the HPV vaccine directly influenced caregiver intent and decision to vaccinate.
Additionally, an evidence-based strategy to improve education and intent includes; offering a 1:1
educational session between the healthcare provider and caregiver (Vadaparamil, 2014). This
strategy was used as a focus for this study.
Providers may not offer the vaccine because they do not typically see children in the
recommended age group of 11-17 years-old, for wellness visits. When children 11-17 years-old
are seen in the office it often occurs after sexual activity has been initiated. Providers
acknowledged that it may be difficult for young adults to locate a healthcare provider who will
accept and file insurance for the vaccinations.
Another barrier reported (Vadaparamil, 2014) is that the providers have a difficult time
getting adolescents to their appointment because they are usually healthy, and the parents do not
seek wellness appointments for them. Many providers in the study reported addressing
vaccination only at wellness visits; however, a few providers were trying to address it at all visits
to avoid “missed opportunities.” Time constraint and the need to prioritize care, however, can
limit how much is covered during an acute care visit. Time constraint was addressed in the study
by limiting participants to only those seeking wellness, non-acute visits to limit the biasing effect
of type of visits on results.
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Family practice providers reported too many competing priorities, such as the requirement
for patients to have depression screening versus providing vaccination recommendations
(Carhart, 2018). Even though providers have the intention of recommending the HPV vaccine,
they may lose track and forget to do it (Carhart, 2018). The study site had issues regarding HPV
vaccination recommendation. Providers found they had time to recommend the vaccine, but
they reported difficulty finding time to provide education or answer questions regarding the
vaccine. This may have left the parent/caregiver feeling uncertain at times and not ready to make
decisions regarding vaccination, therefore, influencing vaccination rates negatively.
Holman (2014) found that parental attitudes towards vaccination were a major barrier to
providing the HPV vaccine to adolescents. For example, a significant number of parents in that
study reported needing more information before vaccinating their children. The parents voiced
concerns about the vaccine’s effect on sexual behavior and demonstrated a low perception of
their children’s risk of contracting HPV. These parents also identified social influences, irregular
preventive care, and vaccine cost as potential barriers. Parents consistently cited health care
professionals’ recommendations, and the information they provide, as one of the most important
factors in their decision to vaccinate their children (Holman, 2014). Vaccination rates for the
study clinic improved when the RN provided a 1:1 brief educational discussion. This finding
suggests that the 1:1 interaction to discuss facts and answer questions can improve vaccination
rates.
In addition, parent/caregivers were very engaged during the educational intervention and
appeared to appreciate knowing more about the vaccine. Further investigation is needed to
determine what specific element of the educational intervention led to this improvement. Brief
education for parents/caregivers may have played a major role in the increased vaccination rates.
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Studies have shown that efforts such as increased education to parent/caregivers can increase
HPV vaccination rates in the primary care setting (Dempsey, 2019).
The increase in vaccination rates is a positive and encouraging finding from this study;
however, the vaccination rates are still low and evidence-based strategies to sustain this
improvement with educational opportunities are needed. An example of an effective sustainment
strategy that worked well in other settings and would be appropriate in this study’s setting is
increasing the use of audio-visual materials and improvement in IT technologies for education.
Dempsey (2019) provided an intervention of a digital video in a study, then parents/caregivers
viewed the video while waiting for the visit. This research suggested the education by video
increased vaccination rates. Another strategy mentioned by Chuang (2017) could be included by
using scorecards or monthly provider audits by an appointed team leader in the clinic to help
providers keep track of their own vaccination rates. The study site utilizes an appointed leader to
track these rates, therefore, contributing to a 100% recommendation rate for the providers in the
clinic.
One of the leading approaches as an evidence-based strategy that helped improve HPV
vaccination rates in the primary care setting is the use of information technology (IT). Dempsey
(2019) found the use of an educational video in the waiting room to overcome knowledge
barriers to receiving the HPV vaccine to be particularly helpful in the primary care setting.
Clinics could also show an educational video to the parent/caregiver while waiting on the
provider. In this study having a dedicated health care professional available to spend time with
the parent/caregiver to provide education was effective as suggested by an increase in
vaccination rates. The educational intervention did have a positive outcome, though not as
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dramatic as anticipated. With a few modifications, the 10-15 minute education intervention could
be incorporated in the surrounding pediatric clinics with minimal expenditure of cost or time.
Other evidence-based strategies include empowerment of staff. It is supported in the
literature that any staff member, including a trained Medical Assistant (MA), could provide this
education. It would cost a clinic approximately $73,000 to assign an RN this responsibility in
comparison to a MA, who would cost around $34,000 (Chuang, 2017). Next steps should include
how best to incorporate this or similar 1:1 educational opportunity into standard practice for all
pediatric clinics. Future practice should include continued education for providers on using
improved IT techniques, such as an interactive I- pad, or module that could be done prior to the
patient visit to assess knowledge of HPV. In addition, a policy change to consider, would be
adding an educational printout to the mandatory school paperwork as a form that both
adolescents and their caregivers could review that would provide necessary information
regarding the HPV vaccine. These methods are time efficient and provide a collaborative
approach that do not overburden the caregiver, provider, or office staff. These are all ways to
improve the caregiver intent to vaccinate, therefore hopefully leading to a further increase in
vaccinations.
Implications for Practice
Review of the literature suggested the need to explore the educational needs and methods
utilized to provide education, among a variety of community settings (Chuang, 2017). Research
also indicated that knowledge of the HPV vaccine and need for further education was warranted
(Chuang, 2017). Implementing a 1:1 educational session may have increased rates for this
specific clinic, but a more robust longitudinal study would need to be conducted in the future.
Next steps should include how best to incorporate this 1:1 educational opportunity into standard
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practice. It is supported in the literature that any staff member, including an MA could provide
this education. It would cost a clinic around $73,000 to assign an RN this responsibility in
comparison to a MA, which would cost around $34,000 (Chuang, 2017).
An evidence-based strategy that should be considered for practice is training and
empowering staff to help streamline the process (Chuang, 2017). Future practice should include
continued education for providers on the importance of educating parent/caregivers of
adolescents ages 11-17 years old, using improved IT techniques (Dempsey, 2019). One way to
remind providers to provide further education on the vaccine would be to place posters and
prompts in the patient rooms and in their individual office spaces (Chuang, 2017). Another
beneficial method would be for the MA/RN to give the parent/caregiver a copy of an educational
pamphlet to review while waiting. Additionally, it would also be worthwhile to implement a
tracking measure to monitor screening and education adherence. The study clinic utilizes a team
member to track current vaccination rates and report them to providers, but they may benefit
from education adherence being added to the electronic health records as a reminder.
Limitations
Limitations of this study included a small sample size of patients seen during this time
period for non-acute visits, aged 11-17 years old. It was emphasized by the clinic that their
highest numbers of wellness visits occur from April to September; this study period was from
October to February. The increase of adolescent visits normally take place from April to the
beginning of the new school year due to the need for sports physicals during that time. During
the winter months there are an abundance of children seen for sick visits, so the numbers were
considerably lower.
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The chart review method could have focused only on children that had never received a
dose of the HPV vaccine. This result would have provided more concise data aimed towards the
focus of this study. Additionally, I did not assign a unique identifier to intervention participants,
thus, participants were unable to be matched with survey responses. This collection method
would have helped the study match responses to decisions as to whether or not they chose to
vaccinate.
In addition, this study took place at only one clinic over a period of a few months. Other
settings and/or other populations may have yielded different results. The results were not
generalizable due to using a convenience sample. This study took place at only one clinic over a
period of a few months. Increasing the study reach to include multiple locations could have
increased the number of parent/caregivers willing to participate in the study.
Conclusion
In conclusion, more than 90% of cervical cancer cases are caused by the human
papilloma virus, and administration of the HPV vaccine to adolescents can reduce or eliminate
this risk. However, vaccination rates for HPV among adolescents are still very low, at only 60%
vaccinated (Smulian, Mitchell, & Stokley, 2016). A 1:1 educational discussion between the
health care provider and the parent/caregiver is an effective evidence-based strategy that has
improved vaccination rates in other studies, as well as the study described in this paper. Health
care providers are one of the most important factors that influence parental/caregiver vaccination
decisions, and we need to make sure there is sufficient time and opportunity for this interaction
to occur between the caregiver and the health care provider. In addition to knowledge,
misperceptions, and other barriers mentioned in this study, targeted interventions need to be
determined and aimed towards eliminating these barriers for future studies.
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Patients may only see their primary care provider once yearly or for sick visits, so
educating the caregiver on the importance of vaccinating their child during these visits is
essential, or they may go unvaccinated. Appropriate screening, overcoming parent/child
knowledge barriers, and ultimately administration of the vaccine will decrease the incidence of
HPV- related cancers (Harris, 2017).
Health care providers are one of the most important factors that influence vaccination
decisions (Holman, 2014). This finding was supported in this study, thus, we need strategies that
create ample opportunity for parents/caregivers to receive education and an opportunity for
discussion with their health care providers. Because of the significant impact HPV vaccination
can have on health outcomes, providers and office staff must continue to make efforts to increase
the intent to vaccinate for parents and caregivers. The educational intervention is a brief way of
increasing awareness and intent to vaccinate for HPV in the primary care setting. Therefore, it is
imperative that primary care providers work toward efforts to increase vaccination coverage. It is
essential that health care providers and public health organizations initiate efforts to increase
HPV vaccination doses through completion of the two or three-dose series (Smulian, Mitchell, &
Stokley, 2016).
In this study after a brief educational intervention that focused on increasing intent to
vaccinate, there was an increase in administration of the HPV vaccine. However, vaccination rates
were still low and the longer-term vaccination rates remained unchanged. There remains much
need for improvement. The preliminary results from this study are indeed promising however in
the future, a longitudinal and more robust study needs to be done to see if the educational
intervention contributed to this increase in vaccination rates. Future work should seek to identify
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which specific elements of this intervention contributed to the success, and strategies to ensure
sustainability of these improvements.
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Appendix A. Educational Intervention Outline
With each non-acute visit meeting age criteria 11-17 years old:
•

Supportive staff will provide cover letter and educational pamphlet regarding HPV
vaccine to each parent/caregiver at the beginning of the visit.

•

The staff will reinforce that the primary investigator will be providing education on the
kvaccine that same day

•

Any questions the parent/caregiver may have will be routed to the primary investigator

•

Parent/caregiver will be asked to read cover letter introducing the study. Parent/caregiver
will also be requested to read educational pamphlet and decide if they are interested in the study
with the PI.

During each visit:
•

If parents/caregivers are interested in the study the primary investigator will receive
verbal consent and educate willing parent/caregivers on receiving HPV vaccination. The
PI will distribute the pre-educational intervention survey prior to starting the educational
intervention.

•

The primary investigator will collect survey from parent/caregiver prior to beginning the
educational intervention.

•

The parent/caregiver will be informed of the intent to have the child receive the HPV
vaccine that day.

•

Any questions the parent/caregiver may have regarding the vaccine will be discussed.

•

If the parent/caregiver decide to wait on vaccination, it will be requested that they take
the educational pamphlets home with them and set up a future appointment with the
provider to discuss vaccine further.
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Appendix B. Consent Form

Institutional Review Board
AGREEMENT TO PARTICIPATE IN A RESEARCH STUDY
MEDICAL RESEARCH INFORMED CONSENT
Title of research study: Improving Rates of First Dose Administration of the HPV vaccine
Investigator: Lindsey Brough, NP Primary Investigator and Scarlett Mikesell-Pierce UK DNP
student Co-Investigator

PARTICIPANT NAME ______________________________________________

Why am I being invited to take part in a research study?
You are being invited to take part in a research study about overcoming parent/child knowledge
barriers to receiving the HPV vaccination. You are being invited to take part in this research
study because you are the parent/caregiver of an adolescent patient at St. Vincent Pediatric
Clinic, where the study is taking place. All parent/caregivers of patients meeting age criteria 1117 years old will be invited to participate in this study.
What should I know about a research study?
You will not get any personal benefit from taking part in this study. If you decide to take part in
this study, it should be because you want to volunteer. Your adolescent will not lose any benefits
or rights they would normally have if you choose not to volunteer. You can stop at any time
during the study and keep the benefits and rights you had before volunteering.
Why is this research being done?
The purpose of this study is to increase first dose administration of the HPV vaccine by
providing an educational intervention that increases parent/caregiver knowledge regarding the
vaccine.
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How long will the research last and what will I need to do?
The research procedures will be conducted at St. Vincent Pediatric Clinic. The study will take
place during normal clinic hours during your scheduled visit at the clinic. You will not be asked
to volunteer any additional time.
Is there any way being in this study could be bad for me?
The risks to participating in this study may include some emotional discomfort due to the nature
of HPV. You may experience a previously unknown risk or side effect of HPV.
Will being in this study help me in any way?
You will not get any personal benefit from taking part in this study.
What happens if I do not want to be in this research?
If you do not wish to participate, there are no other choices except not to take part in the study.
Who can I talk to?
The person in charge of this study is Lindsey Brough, NP from St.Vincent Pediatric Clinic and
Scarlett Mikesell-Pierce, BSN, RN of the University of Kentucky, College of Nursing. She is
being guided in this research by Elizabeth Tovar, Phd, RN, FNP-C. There may be other people
on the research team assisting at different times during the study.
What happens if I say yes, I want to be in this research?
You will be asked to participate in an educational intervention that discusses the HPV vaccine.
Educational pamphlets will be provided. Any questions regarding the HPV vaccine will be
answered and open for discussion.
What happens if I say yes, but I change my mind later?
You can leave the research at any time it will not be held against you.
Is there any way being in this study could be bad for me? (Detailed Risks)
The risks to participating in this study may include some emotional discomfort due to the nature
of HPV. You may experience a previously unknown risk or side effect of HPV.
What happens to the information collected for the research?
We will make every effort to keep confidential all research records that identify you to the extent
allowed by law.
Your information will be combined with information from other people taking part in the study.
When we write about the study to share it with other researchers, we will write about the
combined information we have gathered. You will not be personally identified in these written
materials. We may publish the results of this study; however, we will keep your name and other
identifying information private.
We will make every effort to prevent anyone who is not on the research team from knowing that
you gave us information, or what the information is. No identifying information will be recorded
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with the discussion, and this data will be password protected and only accessed by the principal
investigator.
You should know, however, that there are some circumstances in which we may have to show
your information to other people. For example, the law may require us to show your information
to a court or to tell authorities if you report information about a child being abused or if you pose
a danger to yourself or someone else.
Please be aware, while we make every effort to safeguard your data once received, given the
nature of online information involving the internet, we can never guarantee the confidentiality of
the data while still en route to us.
Will the researchers benefit from my participation in this study?
The researchers will not receive any rewards or payment for you taking part in this study.
What else do I need to know?
Before you decide whether to accept this invitation to take part in the study, please ask any
questions that might come to mind now. Later, if you have questions, suggestions, concerns, or
complaints about the study, you can contact the investigator, Scarlett Mikesell-Pierce (502) 6447849 or email at scarlett.mikesell@uky.edu. If you have any questions about your rights as a
volunteer in this research, contact the staff in the St. Vincent IRB Office at 317-338-2194. We
will give you a signed copy of this consent form to take with you.
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Your signature documents your permission to take part in this research. Please keep a copy of
this Informed Consent for your records.
Signature of subject

Date

Printed name of subject
Signature of person obtaining consent

Date

Printed name of person obtaining consent

Signature of Legally Authorized Representative

Date

Printed name of Legally Authorized Representative
Check Relationship to Subject:
Legal Guardian or Legally Authorized Representative for Medical Care (LARM)
Spouse
Adult Son or Daughter
Mother or Father
Adult Brother or Sister
Other, explain:
Reason subject is unable to sign for self:
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RESEARCH PATIENT BILL OF RIGHTS

I have been asked to participate in a research study. Before I make a decision on whether
or not I want to participate in this study, I have the right:
1.

To be told the reason why this study is being done.

2.

To be told how the study will be done and what kind of medication or
device will be used

3.

To know the different types of side effects to expect from my participation
in the study.

4.

To know what benefits I will receive from my participation in this study.

5.

To be told what other treatment is available for me, including the risks and
benefits.

6.

To be told what other treatments are available to me after the study has
been completed.

7.

To be given an opportunity to ask any questions concerning the medical
experiment or the procedures involved.

8.

To stop the study at any time and know I will continue to receive good
care.

9.

To receive a copy of the patient rights and the signed and dated informed
consent form.

10.

To make up my mind about being part of the study without feeling forced
to participate.
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Appendix C. Cover Letter
Cover Letter

To Participant:
My name is Scarlett Mikesell-Pierce of the University of Kentucky, College of
Nursing and I am being guided in research by Lindsey Brough, NP at St. Vincent
Pediatric clinic and Elizabeth Tovar, PhD, RN, FNP-C. There are no institution(s) or
companies involved in the study through funding or financial support, cooperative
research, or by providing equipment or materials for this study.
I am inviting you to take part in a research study about human papilloma virus (HPV)
vaccination. You will be asked to complete a short survey/questionnaire before and
after a brief educational discussion about HPV vaccination. The
surveys/questionnaires will help me to gain information about your understanding and
knowledge regarding the HPV vaccine. Each survey will take about 2-5 minutes to
complete and the educational discussion will take about 10 minutes. I hope to make
evidence-based recommendations from the survey results on ways to increase your
knowledge and overcome barriers in the clinic regarding the HPV vaccination.
Although you will not get personal benefit from taking part in this research study,
your responses may help us understand more of the barriers that parents/children
encounter when recommended the HPV vaccine.
We hope to receive completed questionnaires from all the patients in the identified
age group at St. Vincent Pediatric Clinic, and your answers are important to us. Of
course, you have a choice about whether or not to complete the survey/questionnaire,
but if you do participate, you are free to skip any questions or discontinue at any time.
Participation in this study is voluntary, and if you do not choose to complete the
survey there will no penalties or loss of benefits. If you do not wish to complete this
survey, there are no alternative surveys.
Your response to the survey is anonymous which means no names will appear or be
used on research documents, or be used in presentations or publications. Your name
will not be recorded on the surveys.
If you have questions about the study, please feel free to ask; my contact information
is given below. If you have complaints, suggestions, or questions about your rights as
a research volunteer, contact the staff in the St. Vincent IRB at 317-338-2194. Thank
you in advance for your assistance with this important project. Please complete the
pre-education survey if you want to participate in the study.
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Sincerely,
Scarlett Mikesell-Pierce, BSN, RN
College of Nursing, University of Kentucky
PHONE: 502-644-7849
E-MAIL: scarlett.mikesell@uky.edu
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Appendix D. Chart Audit Tool
Improving Rates of First Dose Administration of the HPV vaccine
Chart Audit Tool
Study number:_______________
Gender:_____________________
Age:________________________
Race:_______________________
At the patient’s 11/12 year old well-child visit, were the following documented:
Information
Was counseling on
the HPV vaccine
provided?

Yes

No

Comments

By: ___ CMA
____NP/MD

Was the HPV
vaccine offered?
Patient’s response
if vaccine was
offered
Was the HPV
vaccine series
initiated today?
Was the vaccine
series initiated or
completed prior to
this visit?

__ Accepted
__ Deferred
__ Declined

Doses given (Y/N)? #1_________
To ages 11-14
On-time? Y/N

#2__________
Y/N

Doses given (Y/N)? #1_________
To ages 15-17
On-time? Y/N

#2__________ #3_________
Y/N
Y/N
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Appendix E. Parent/Child Pre-Educational Intervention Survey
Parent/Child Pre- Educational Intervention Survey
Please circle your response:
1. Have you heard of the HPV vaccine?

YES

NO

2. The HPV vaccine is recommended for children 11-17 years of age.
FALSE

TRUE

3. The HPV vaccine is recommended for cancer prevention caused by the human papilloma
virus.
TRUE FALSE
4. Were you planning on getting the HPV vaccine today?

YES

NO

5. How likely are you to get the vaccine today? Rate on scale 0-10 (0 being no chance and
10 very likely)
0

1

2

3

4

5

6

7

8

9

10

6. How likely are you to get the vaccine at some point in the future? Rate on scale 0-10 (0
being no chance and 10 very likely)
0

1

2

3

4

5

6
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7

8

9

10

Appendix F. Parent/Child Post-Educational Intervention Survey
Parent/Child Post- Educational Intervention Survey
Please circle your response:
1. Are you more familiar with the HPV vaccine?

YES

2. Were you planning on getting the HPV vaccine today?

NO
YES

NO

3. How likely are you to get the vaccine today? Rate on scale 0-10 (0 being no chance and
10 very likely)
0

1

2

3

4

5

6

7

8

9

10

4. How likely are you to get the vaccine at some point in the future? Rate on scale 0-10 (0
being no chance and 10 very likely)
0

1

2

3

4

5

6

7

8

9

10

5. How helpful was the educational discussion in helping answer your questions regarding
the HPV vaccine? Rate on scale 0-10 (0 being not helpful and 10 being very helpful)
0

1

2

3

4

5

6

7

8

9

10

6. How helpful was the HPV educational pamphlet? Rate on scale 0-10 (0 being not helpful
and 10 being extremely helpful)
0

1

2

3

4

5

6

7

8

9

10

7. How helpful was the discussion with the primary investigator? Rate on scale 0-10 (0
being not helpful at all and 10 extremely helpful)
0
1
2
3
4
5
6
7
8
9
10
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Appendix G. Educational Pamphlet

B:9”
T:8.5”
S:8”

5

THINGS A PARENT NEEDS TO

KNOW ABOUT HPV

The more we learn about health risks for our children, the more
we can do to help protect them as they grow up. That’s why it’s so
important to get the facts about human papillomavirus (HPV).

1

HPV is a little virus that can
have big consequences.

Being informed is the ﬁrst step in
helping protect your child.

2

not even occur until later in life.

3
HPV infects both genders.
Both males and females can be
infected with HPV. Exposure to the virus
can happen with any kind of adolescent
experimentation that involves genital

5

contact with someone who has HPV —
intercourse isn’t necessary, but it is the
most common way to get the virus.

4

It’s important to talk to your child’s
doctor before they are at risk.

HPV can be spread even when
someone with the virus has
no signs or symptoms.
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THERE’S MORE TO LEARN ABOUT HPV ON THE OTHER SIDE.
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Proofreader:
Studio: Peter Herpich
AE OK Rel:

WC

OK

Date

T:11”

These can develop very slowly and may
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HPV can cause certain
precancers, cancers,
and other diseases.

Appendix H. Staff Member Script for Introduction of Study
Staff member Script for introduction of study
Welcome
Introduction
There is a UK DNP student, Scarlett Mikesell-Pierce, currently working with the St. Vincent
Pediatric Clinic to help us increase our vaccination rates for the HPV vaccine. Here is some
information regarding the study. She will plan to meet with you prior to your visit with the
provider today. Please read through the study while waiting for the provider so that she can
address any questions you might have.
Conclusion
Please let me know if you have any questions while you are waiting.
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Appendix I. HIPPA for Research Purposes

AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION FOR
RESEARCH PURPOSES
St.Vincent is dedicated to protecting the privacy rights of patients. Any uses and disclosures of personal health
information are in accordance with a law called the Health Insurance Portability and Accountability Act of 1996 as
amended by the Health Information Technology for Economic and Clinical Health Act (“HIPAA”). HIPAA is
designed to protect the confidentiality of your health information. This document explains how your health
information will be used and disclosed for the purposes of conducting, monitoring and auditing this study and
describes your rights with respect to that information.
Your personal health information is information about you that could be used to identify you, such as your name,
address, telephone number, photograph, date of birth, social security number, new and existing medical records,
DNA samples, or the types, dates and results of various tests and procedures. This may include information in your
medical and hospital records, as well as information created or collected during the study.
By signing this document you authorize the study physicians and St.Vincent Health and employees (collectively and
individually “Researchers”) to use and disclose the following information about you to each other, the study sponsor
and its representatives, the St.Vincent Health Institutional Review Board, and governmental agencies responsible for
the oversight of this study, including the Food and Drug Administration and any foreign agencies as necessary:
personal health information in your medical and hospital record including medical/surgical history, past and current
medications, vital signs, physical examinations and laboratory results, other assessments, photographs and samples
and analyses of blood, DNA and/or wounds. Your personal health information will be used to conduct the research
study as described in the Informed Consent.
You will not be allowed to review the information collected for the study until after the study is completed. When
the study is over you will have access to the information again.
St.Vincent Health will not condition treatment or payment on whether or not you sign this document. However, this
document is required if you want to participate in the study.
Your authorization to disclose your personal health information in connection with the study will expire at the end
of the study and after all study-related data has been transferred to the sponsor. You may revoke your authorization
to use your personal health information for the study in writing at any time by writing to the St.Vincent Health
Institutional Review Board at 8402 Harcourt Road, Suite 806, Indianapolis, Indiana 46260. You understand that if
St.Vincent Health has already taken action in reliance on your authorization they do not have to undo that action. If
you revoke your authorization to use and disclose personal health information in connection with the study, you will
no longer be able to participate in the study.
Once information is disclosed, it can no longer be controlled by the study physician, St.Vincent Health or by you
and may be re-disclosed by the recipient. Thus, your information would no longer be protected by HIPAA.
A copy of this document will be placed in your medical record and you will receive a copy.
If results of this study or future research you have authorized are published or reported in medical journals or at
meetings, your name will not be included.
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By signing this document, you acknowledge that you have read and understand this Authorization. Further, you
authorize the Researchers to use or disclose your health information in accordance with the terms of this
Authorization.

Printed name of subject
Signature of subject/ authorized legal representative Relationship of authorized legal representative to subject
TMP-509 HIPAA Authorization
St. Vincent Health Institutional Review Board Form Rev. 03/2018

//
Subject’s Date of Birth (mm/dd/yyyy)

Date
XXX-XXSubject’s Social Security Number (last 4 digits only)
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Appendix J. Staff Meeting Invitation
Staff Meeting Invitation

St. Vincent Pediatric Clinic Staff Members
Attention to Providers
Nurses
Medical Assistants
and Front desk staff only

Research Staff Meeting

“Improving Rates of First Dose Administration of
the HPV vaccine”
The purpose of this staff meeting is to inform clinic staff of the
educational intervention that will be taking place in the office
regarding overcoming parent/caregiver knowledge barriers of the
HPV vaccination.

Date
Time
Location

TBA
TBA
St. Vincent Pediatric Clinic
Salem, IN
Lunch will be provided to participating staff
For additional information, please contact:
Scarlett Mikesell-Pierce, BSN, RN
(502) 644-7849
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Appendix K. Staff Meeting Agenda
Improving Rates of First Dose Administration of the HPV Vaccine
Staff meeting agenda
Welcome
Thank you for coming to the staff meeting. I appreciate you being here so that I can inform you
of the research study that is going to be taking place in this clinic.
Introduction
Introduction of principal investigator
Statement of Purpose
I am conducting this staff meeting to share information that I learned from the chart review and
to discover barriers in this practice that affect recommendation of the HPV vaccine to patients.
Your honest input is important and appreciated.
Brief Review of Chart Review Findings
5-10 minute presentation of chart review previously conducted on 11-17-year-old patients
presenting to the clinic for non-acute visits. This chart review will focus on whether the patients
were counseled on the HPV vaccine, whether the vaccine was offered, whether it was
accepted/declined/deferred, and whether it was initiated. Some demographic data including
gender, age, and race will also be recorded. The staff will be informed of my plans to provide an
educational intervention to the parent/caregivers that are willing to participate regarding the HPV
vaccination. Copies of the pre-/post- surveys and educational pamphlet will be available for staff
to review, so they are aware of the tools that I will be using to collect data during the study.
Conclusion
Any further questions/concerns and thank participants again for their contributions.
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Appendix L. Script for Parent/Caregiver Educational Intervention
Script for Parent/Caregiver Educational Intervention
To participant:
My name is Scarlett Mikesell-Pierce of the University of Kentucky, College of Nursing and I am
being guided in research by Lindsey Brough, NP at St. Vincent Pediatric clinic and Dr. Elizabeth
Tovar, PhD, RN, FNP-C.
This is a study about the facilitators and barriers that parents/caregivers encounter when
recommended to receive the human papillomavirus (HPV) vaccine for their adolescent child. I
am planning to provide some educational resources with intent to have your child vaccinated for
HPV. I am available to answer any questions you may have regarding the HPV vaccine.
Of course, you have a choice whether to participate in this educational intervention, but if you do
participate, you are free to ask any questions regarding the vaccine. You can choose to
discontinue this study at any time as well. Participation in this study is voluntary, and if you do
not choose to be vaccinated there will be no penalties or loss of benefits.
Your risk to participating in this study is minimal. Your risk may include emotional discomfort
due to the nature of the vaccine and the development of HPV. Although we tried to minimize
this, some of the discussion may make you feel uncomfortable.
The discussion with myself regarding the HPV vaccine is anonymous which means no names
will appear or be used for research documents, or be used in presentations or publications. The
research team will not know that any information you provided came from you, not even whether
you participated in the study.
If you have any questions about the study, please feel free to ask; my contact information is
given below. If you have any complaints, suggestions, or questions about the rights as a research
volunteer, contact the staff in the St. Vincent IRB at 317-338-2194.
Thank you in advance for your assistance with this important project.
Sincerely,
Scarlett Mikesell-Pierce, BSN,RN
College of Nursing, University of Kentucky
PHONE: 502-644-7849
E-MAIL: scarlett.mikesell@uky.edu
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Table 1. Pre- and Post-Educational Intervention Chart Review
Study Demographics
Phase 1 –Pre
%
(N=100)

Phase 4 –
Post
%
(N=100)

Gender
Male
Female

44%
56%

50%
50%

Race
Caucasian
African-American
Hispanic

97%
1%
2%

94%
4%
2%

p value

.40

.40
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Table 2. Pre- and Post-Educational Intervention Surveys
Intent to Vaccinate
Pre-education
N (%) or Mean (SD)
(N = 15)

Post-education
N (%) or Mean (SD)
(N = 15)

p

Planning on getting vaccinated at
today’s appointment
Yes
No

5 (33%)
10 (67%)

3 (20%)
12 (80%)

Likelihood of getting vaccine
today (0-10)

4.3 (4.5)

6.7 (4.9)

.20

5.9 (4.8)

6.9 (4.1)

.52

Likelihood of getting vaccine in
the future (0-10)

.41
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Table 3. Vaccination rates for administration of the HPV vaccine
Chart Audits Pre- and PostPreeducation
N (%)

Posteducation
N (%)

p

Vaccinated

9 (19.1%)

20 (40.8%)

.021*

Not Vaccinated

38 (80.9%)

29 (59.2%)

Total

47 (100%)

49 (100%)

Table 4. Pre- and Post- Clinic Vaccination Rates
Pre-education
n (%)

Post-education
n (%)

p

Vaccinated

303 (58.4%)

345 (64.3%)

.044

Not
Vaccinated

216 (41.6%)

357 (59.2%)

Total

520 (100%)

535 (100%)
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Table 5. Pre-educational intervention knowledge of the HPV vaccine, (N=15)
Intervention Group
Question

Pre-education
N (%)

Heard of the HPV vaccination
Yes
No

12 (80%)
3 (20%)

The HPV vaccine is recommended for children 11-17 years of age
True
False

12 (80%)
3 (20%)

The HPV vaccine is recommended for cancer prevention caused by the
human papilloma virus?
True
False

15 (100%)
0 (0%)
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Table 6. Post- Educational Intervention Survey Results
Question

Mean

SD

How helpful was the educational discussion? (use scale 0-10,
with 0 being not helpful and 10 being very helpful)

9.27

1.3

How helpful was the educational HPV pamphlet? (0-10)

9.4

1.3

How helpful was the discussion with the principal
investigator? (0-10)

9.73

1.0
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